This time I’m going to focus on one company and its view on pharma’s digital commercial strategy ... was the high level of uncertainty about its effects. In March 2020 Pfizer began ...

All this negativity, however, does open up an opportunity for investors to buy the stock at a discount. Despite being a top ...

Pfizer has just made venture capital firm Flagship ... making waves in the biotech sector in the last few years with its strategy of creating companies based on biopharma technology platforms ...

Pfizer used the investor event to formally introduce its new business division dedicated to cancer research and to lay out a long-term strategy for it through the end of the decade. That oncology ...

Although Pfizer (NYSE:PFE) reiterated 2025 financial guidance issued in December, the midpoints of the ranges for revenue and EPS are below consensus figures. The pharmaceutical giant is ...

My DCF analysis suggests stock ought to be valued ~$50, but this depends on the business becoming ... believing “this will be Pfizer's year” is a comparable strategy. Pfizer stock began ...

With just one asset in weight loss moving through the clinic, Pfizer targets the space for potential dealmaking, as well as bringing assets over from China.

A potential combination with AstraZeneca aligns with Pfizer’s current structure and fully supports its existing strategy to build world-class ... heritage as an innovation-driven biopharmaceutical ...

In early 2023, Pfizer (NYSE: PFE) began looking to offload the Durham facility as part of a shift in the company's research and development strategy. By the end of 2023, the company confirmed ...

BMO Capital markets analyst Evan Seigerman said Pfizer's forecast is already conservative, and with COVID products no longer seen as a core business, investor reaction to lower volumes could be muted.

Pfizer had largely honed in on breast and prostate cancers, cancer chief Andy Schmeltz told Business Insider earlier ... Read more: Pfizer has a new strategy for fighting cancer that could ...